

## Prevalence of SARS-CoV-2 Infections in a Pediatric Orthopedic Hospital

Ghalib Bardai, Jean A. Ouellet, Thomas Engelhardt, Gianluca Bertolizio, Zenghui Wu, Frank Rauch  
Shriners Hospital for Children - Canada, Montreal, Quebec, Canada

**Correspondence:** [frauch@shriners.mcgill.ca](mailto:frauch@shriners.mcgill.ca)

**Key words:** Antibody; Covid-19; Children; Health Care Workers; SARS-CoV-2

### Abstract

This project assessed the prevalence of active and past infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a specialized pediatric institution that did not provide care for coronavirus disease 2019 (Covid-19). The study was performed in Montreal, the city with the highest number of Covid-19 cases in Canada during the early phase of the pandemic. Testing for SARS-CoV-2 RNA in 199 individuals (39 children, 61 accompanying persons, 99 hospital employees) did not reveal active infection in any of the study participants. However, 22 (11%) of study participants had SARS-CoV-2 IgG antibodies, indicating prior infection. Ten of these participants did not report symptoms compatible with Covid-19 in the 6 months prior to the study. Thus, although no evidence for active infection was found within the institution, consideration should be given to regular staff testing to detect asymptomatic spreading of SARS-CoV-2. In addition, it could be useful to test accompanying persons in children presenting for surgical procedures.

## **Introduction**

Montreal has the highest incidence of coronavirus disease 2019 (Covid-19) among cities in Canada, with 29,596 reported cases as of August 22, 2020, representing about one quarter of all reported cases in Canada (1). The present study was performed in a pediatric institution located in Montreal that provides elective-only specialized services for children with musculoskeletal conditions, such as pediatric orthopedics, rehabilitation and medical therapies. The institution does not provide care for infectious diseases; patients with known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are therefore treated at other institutions. At the start of the Covid-19 pandemic, a set of measures was implemented to minimize the risk of infection within the institution, such as screening each person entering the hospital, mandatory temperature checks at the entrance, wearing face masks within the building, reducing the number of clinic visits and testing for SARS-CoV-2 RNA (using nasopharyngeal swabs) in patients scheduled for surgery (Figure 1).

The aim of this project was to assess whether the institution remained free of SARS-CoV-2 infections after these countermeasures were implemented. To this end, patients, accompanying persons and employees were offered testing for active virus infection by examining for SARS-CoV-2 RNA in saliva. In addition, blood samples were obtained to test for SARS-CoV-2 IgG antibodies as indicators of past virus infection. As the sensitivity of detecting SARS-CoV-2 RNA in saliva samples was not well established at the start of the project, participating hospital employees underwent weekly sampling to increase the probability of identifying active infection with SARS-CoV-2.

## **Subjects and Methods**

Study participants were recruited at Shriners Hospital for Children – Canada in Montreal, Canada, between June 10 and July 27, 2020. All participants were asymptomatic for SARS-CoV-2 IgG antibodies infection at the time of recruitment, as only asymptomatic individuals had access to the hospital. The study population was comprised of 200 participants. This included 100 employees (about

one third of the full-time staff) and 100 patients or individuals accompanying patients. All study participants or their legal guardians provided informed consent. The study was approved by the Institutional Review Board of McGill University (study number A05-M45-20B).

Study participants who were patients at the hospital or persons accompanying them had a single study visit. Hospital employees underwent 5 study visits on consecutive weeks. At each study visit, participants were asked to provide 2.5 ml of saliva into a sterile container and blood samples (5 ml) were obtained in serum tubes. Saliva samples were stored at -80C until analysis, serum was stored at -20C.

Saliva samples were tested for the presence of SARS-CoV-2 virus using real-time PCR (ABI 7500 Fast, Applied Biosystems). Viral nucleic acid isolation for SARS Cov-2 was performed using the Applied Biosystems MagMAX Viral/Pathogen kit on a Kingfisher (Thermo Fisher) instrument according to the manufacturers protocol. Extracted RNA was analysed using a commercially available kit (Taqpath RT-PCR COVID-19 Combo Kit with TaqPath 1-Step Multiplex Master Mix, Applied Biosystems). The method assesses for the presence of three SARS-CoV-2 target genes (Orf1a/b, N and S). Data analysis and interpretation of PCR data was performed using the Applied Biosystems COVID-19 Interpretive Software v1.2.

Serum samples were tested for the presence of SARS-CoV-2 IgG antibodies using a commercially available enzyme-linked immunosorbent assay (ELISA) targeting SARS-CoV-2 Spike (S2) and Nucleoprotein (N) (Mologic, Omega diagnostics, UK) following the manufacturer's instructions. Each plate had a diluent (negative), cut off and positive controls. Results were considered positive if they were 10% above the cut off value. Extensive validation of this assay found a specificity of 97% (2).

Group differences in categorical variables were tested for significance using the chi-square test. All tests were two-tailed and throughout the study P-values <0.05 were considered significant. Calculations were performed using SPSS Software Version 24 for Windows (SPSS, Inc., Chicago, IL, USA).

## Results

Results were obtained from 199 individuals (139 females, 60 males) (Table 1). One of the employees left the institution before any sample was obtained; therefore, results are available on 199 study participants. None of the study participants had detectable SARS-CoV-2 RNA in saliva samples, but 22 (11%) study participants were positive for SARS-CoV-2 IgG antibodies in serum samples. The difference in seroprevalence between patients, accompanying persons and hospital employees was not statistically significant ( $P = 0.75$ ).

Of the 22 seropositive individuals, 12 reported symptoms compatible with Covid-19 in the 6 months prior to the study. Thus, 10 seropositive study participants (1 child, 3 accompanying persons, 6 employees) were considered asymptomatic. Eleven (50%) seropositive individuals had undergone prior SARS-CoV-2 testing by nasopharyngeal swab 4 or more weeks prior to the present study, which had yielded a positive result in 5 of these study participants. Four individuals (3 employees, 1 accompanying person) had provided care to patients with Covid-19 infections at other health care institutions, the other seropositive study participants had no known exposure to the virus.

Among hospital employees, SARS-CoV-2 IgG antibodies were found in 3 of 20 (15%) operation room personnel, in 5 of 44 (11%) health care workers from other departments and in 4 of 35 (11%) employees who did not have direct patient contact ( $P = 0.91$ ). Eleven employees were seropositive at the first study visit. One employee had SARS-CoV-2 antibodies only at the last study visit, even though no SARS-CoV-2 RNA had been found in any of the employee's saliva samples. Among the 12 employees with SARS-CoV-2 IgG antibodies in at least one sample, 3 (25%) had a negative antibody test result by the time of their last study visit.

## Discussion

In this study we found that none of the study participants had detectable active infection with SARS-CoV-2 virus at the time of the study. A prior study had found that use of saliva samples was a sensitive

method to detect SARS-CoV-2 in asymptomatic health care workers (3). However, 11% of study participants had IgG antibodies against SARS-CoV-2, indicating prior infection with the virus. Seroprevalence was similar between hospital employees, patients and accompanying persons and did not vary with the type of work performed by employees.

The prevalence of SARS-CoV-2 IgG antibodies among hospital employees in the present study is similar to the observations in a New York hospital system, where 13.7% of health care workers were seropositive (4). Our findings are also in line with a report from a large Belgian tertiary health care center, where seroprevalence was similar among employees who had patient contact and those without patient contact (5). However, the overall seroprevalence of 11% in the present study is higher than what has been reported in a study on blood donors in Montreal that was conducted at approximately the same time as the present study (between May 25 and July 9), where only 3% were seropositive (6). Even though this study used a different IgG antibody than the present study, it appears that the SARS-CoV-2 seroprevalence is higher among individuals who volunteer for participation in a SARS-CoV-2 study than among blood donors.

While 12 study participants with SARS-CoV-2 antibodies reported symptoms compatible with Covid-19 infection in the 6 months prior to the study, 10 individuals, including 6 employees, appeared to have had asymptomatic infection. The fact that 6 of the 99 participating employees had undergone apparently asymptomatic infection suggests that testing of asymptomatic employees for virus RNA would have been necessary to identify their SARS-CoV-2 infection. Nevertheless, the observation that one employee developed antibodies despite repeatedly negative saliva tests shows that even repeated testing may not correctly identify all individuals with SARS-CoV-2 infection.

The finding that 3 of the 12 seropositive study participants had a negative SARS-CoV-2 antibody result at the last study visit is in accordance with previous reports that in up to 40% of those recovering from mild disease, SARS-CoV-2 antibodies fall to undetectable levels within 2-3 months (7). However, recent data suggest that antibodies against the N protein decline faster than antibodies against the S2

protein (8). The ELISA used in the present study used antibodies directed against both of these proteins and may therefore reflect the decline in N protein specific antibodies.

Thus, while no case of active SARS-CoV-2 infection was detected among individuals within our health care institution there was evidence for prior infection in 11% of study participants. Consideration should be given to regular staff testing to detect asymptomatic spreading of SARS-CoV-2. In addition, it could be useful to test accompanying persons in children presenting for surgical procedures.

### **Acknowledgements**

We thank Michaela Durigova, Marie-Josée Giguère and Elizabeth Parr for organizational support, Vanessa Pépin, Carine Dahan, Carla Evangeliste, Souad Rhalmi and Juliana Marulanda for sample procurement, and Charlotte El-Mir, Sami Abdullah and Faviola Huapaya-Wong for sample analysis. The study was supported by the Shriners of North America. ELISA IgG antibody plates were donated by Mologic.

## References

1. Situation of the coronavirus (COVID-19) in Québec 2020 [Accessed 22-Aug-2020. Available from: <https://www.quebec.ca/en/health/health-issues/a-z/2019-coronavirus/situation-coronavirus-in-quebec/>].
2. Adams ER, Augustin Y, Byrne RL, Clark DJ, Coccozza M, Cubas-Atienzar AI, Cuevas LE, Cusinato M, Davies BMO, Davies M, Davies P, Duvoix A, Eckersley NM, Edwards T, Fletcher T, Fraser Aj, Garrod G, Hadcocks L, Hu Q, Johnson M, Kay GA, Keymer K, Kirwan D, Klekotko K, Lewis Z, Mason J, Mensah-Kane J, Menzies S, Monahan I, Moore CM, Nebe-von-Caron G, Owen SI, Planche T, Sainter C, Schouten J, Staines HM, Turtle L, Williams C, Wilkins J, Woolston K, Sall AA, Fitchett JRA, Krishna S. Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration. medRxiv 2020. doi: 10.1101/2020.04.29.20082099
3. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF, Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M, Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. medRxiv 2020. doi: 10.1101/2020.08.03.20165233
4. Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, Davidson KW, Northwell Health C-RC. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA 2020. doi: 10.1001/jama.2020.14765
5. Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, Heylen L. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA 2020. doi: 10.1001/jama.2020.11160

6. Hema-Quebec. Blood donor seroprevalence study 2020 [Accessed 21-Aug-2020. Available from: <https://www.hema-quebec.qc.ca/publications/communiqués/archives/2020/communiqués-2020/etude-seroprevalence-resultats.en.html>].
7. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020;26:1200-4. doi: 10.1038/s41591-020-0965-6
8. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson MR, Bradshaw C, Weinkauff CC, Bime C, Erickson HL, Knox K, Bixby B, Parthasarathy S, Chaudhary S, Natt B, Cristan E, El Aini T, Rischard F, Champion J, Chopra M, Insel M, Sam A, Knepler JL, Capaldi AP, Spier CM, Dake MD, Edwards T, Kaplan ME, Scott SJ, Hypes C, Mosier J, Harris DT, Lafleur BJ, Sprissler R, Nikolich-Zugich J, Bhattacharya D. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. *medRxiv* 2020. doi: 10.1101/2020.08.14.20174490

Table 1. Demographics of study population and study results.

	Patients	Accompanying Persons	Employees
N	39	61	99
Females, N (%)	24 (62%)	41 (67%)	74 (75%)
Age (years)	15.6 (13.4; 16.8)	47.1 (41.4; 50.8)	42.5 (32.5; 52.5)
SARS-CoV-2 positive by PCR, N (%)	0 (0%)	0 (0%)	0 (0%)
SARS-CoV-2 IgG antibody positive, N (%)	3 (8%)	7 (12%)	12 (12%)

Results are shown in N (%) or as median (interquartile range).




Figure 1. Study period in relation to infection rate in the Montreal area (data from: <https://santemontreal.qc.ca>). The timing of institutional countermeasures (i.e., wearing of face masks, mandatory temperature check at the hospital entrance; screening for Covid-19 related symptoms) is also indicated.